Brookline Capital Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $10

Brookline Capital has initiated coverage on Biomea Fusion (NASDAQ: BMEA) with a Buy rating. The firm has set a price target of $10 for the stock.